Grants for Public Housing Authorities

The purpose of the Pathway to Independence Award in Tobacco Regulatory Research (K99/R00) is to increase and maintain a strong cohort of new and talented independent investigators conducting research that will inform the development and evaluation of regulations on tobacco product manufacturing, distribution, and marketing. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions

The purpose of the Mentored Research Scientist Career Development Award in Tobacco Regulatory Research (K01) is to provide support and protected time (three, four, or five years) for an intensive, supervised career development experience in biomedical, behavioral, and social science research that will inform the development and evaluation of regulations on tobacco product manufacturing, distribution, and marketing and that will lead to research independence. Research projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP) as mandated by the Family Smoking Prevention and Tobacco Control Act (FSPTCA), Public Law 111-31.

The purpose of the Mentored Research Scientist Career Development Award in Tobacco Regulatory Research (K01) is to provide support and protected time (three, four, or five years) for an intensive, supervised career development experience in biomedical, behavioral, and social science research that will inform the development and evaluation of regulations on tobacco product manufacturing, distribution, and marketing and that will lead to research independence. Research projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP) as mandated by the Family Smoking Prevention and Tobacco Control Act (FSPTCA), Public Law 111-31.

The purpose of the Pathway to Independence Award in Tobacco Regulatory Research (K99/R00) is to increase and maintain a strong cohort of new and talented independent investigators conducting research that will inform the development and evaluation of regulations on tobacco product manufacturing, distribution, and marketing. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions

This funding opportunity supports research institutions and organizations in developing innovative HIV vaccine candidates through preclinical and manufacturing processes, with a focus on partnerships and readiness for clinical trials.

This grant provides funding for researchers to develop innovative technologies and resources that improve the reliability and applicability of animal models in biomedical research across various diseases and organ systems.

The ORIP grant supports research projects that aim to improve the validity and reliability of animal research through the development of widely applicable technologies and resources, focusing on studies that impact multiple organ systems or are relevant to various NIH Institutes and Centers.

This grant provides funding to early career researchers proposing innovative studies on the genetics or epigenetics of substance use disorders, aiming to foster new insights and advancements in addiction research.

This grant provides funding to early-stage researchers exploring innovative chemical and pharmacological approaches to understanding and treating substance use disorders.

This funding opportunity supports early-career rehabilitation researchers in conducting small-scale studies that will help them gather preliminary data for future larger research projects focused on improving recovery and rehabilitation for individuals with disabilities.

This funding opportunity provides small grants to early-career researchers who have received specific NHLBI K awards, allowing them to expand their research projects or explore new studies that build on their previous work.

This funding opportunity supports U.S. institutions and organizations in developing animal models and biological resources to advance research on Down syndrome and its related health conditions.

This funding opportunity supports research that investigates how sex and gender differences impact health outcomes and disease management, targeting a wide range of eligible organizations, including universities and nonprofits.

This funding opportunity supports research projects that explore and address the health disparities related to HIV and substance use among underserved racial and ethnic minority populations in the U.S.

This funding opportunity provides financial support for educational programs that train new researchers in Down syndrome to improve understanding and treatment of co-occurring health conditions throughout the lifespan.

This funding opportunity supports research projects that aim to reduce health disparities related to HIV and substance use among underserved racial and ethnic populations in the U.S.

This grant provides funding for researchers to develop and validate innovative, safe, and noninvasive methods for real-time assessment of placenta development and function throughout pregnancy, ultimately aiming to improve maternal and fetal health outcomes.

This funding opportunity supports researchers in developing innovative, safe, and noninvasive methods to assess the placenta's development and function throughout pregnancy, with the goal of improving maternal and fetal health outcomes.

This funding opportunity provides financial support and mentorship for researchers with doctoral degrees to develop their careers in health services research, focusing on improving healthcare quality and equity in the United States.

The NIAID Research Opportunities for New and "At-Risk" Investigators to Promote Workforce Diversity (R01 Clinical Trial Optional), designated as PAR-22-241, is a funding opportunity issued by the NIH's National Institute of Allergy and Infectious Diseases (NIAID). The program targets New Investigators (NI) and At-Risk Investigators from underrepresented backgrounds in the biomedical, clinical, behavioral, and social sciences. New Investigators are those who have not previously secured substantial independent NIH funding, while At-Risk Investigators are those with previous funding but face a lack of funding in the following fiscal year unless a new grant is awarded. This initiative aligns with the goals of the 21st Century Cures Act to encourage new researchers, foster early independence, and support a more diverse scientific workforce. This funding announcement supports research relevant to the NIAID mission, including the study and treatment of infectious, immunologic, and allergic diseases. Research areas of focus include microbiology, immunology, infectious diseases, AIDS, transplantation, and emerging diseases. Although clinical trials are optional, applicants proposing NIH-defined clinical trials must consult with NIAID before submission. The funding opportunity is open to projects that advance diversity in the R01 investigator pool and those promoting representation from underrepresented groups in line with NIH’s interest in enhancing diversity across all health-related fields. To apply, investigators must be affiliated with U.S.-based higher education institutions or eligible nonprofits and for-profit organizations. This opportunity is also open to minority-serving institutions, such as Hispanic-serving Institutions, HBCUs, and Tribally Controlled Colleges and Universities. Non-domestic (non-U.S.) entities are not eligible, although foreign components of U.S. organizations are permitted. An essential part of the application process is an Eligibility Certification Letter from the applicant institution verifying the applicant’s eligibility and alignment with the program’s diversity objectives. Applications missing this letter will be considered incomplete. Funding levels are based on the project’s actual needs and are not capped, with a project duration of up to five years. NIAID also expects applicants to allocate funding in their budgets for mandatory attendance at a workshop designed to foster networking, collaboration, and professional growth among awardees, to be held every three years starting in 2025. Additional support for necessary accommodations for researchers with disabilities may also be included in the budget. The application process requires thorough adherence to NIH’s submission guidelines, which include registrations with SAM, Grants.gov, eRA Commons, and the acquisition of a UEI. Applications are accepted electronically through the NIH ASSIST system, Grants.gov Workspace, or a system-to-system solution. The next deadline cycle follows NIH’s standard due dates, with submissions due at 5:00 PM local time. Applicants are advised to submit early to address potential errors before the due date. Applications will be evaluated on scientific merit and alignment with program priorities, using criteria focused on the significance of the research, investigator qualifications, project innovation, approach, and institutional environment. Specific review criteria for clinical trials include the adequacy of study design, data management, and statistical analysis plans. Following peer review, recommended applications will receive secondary review by the NIAID advisory council. Final award decisions consider both scientific merit and relevance to NIAID’s mission and diversity goals.